Home » Stocks » PRTK

Paratek Pharmaceuticals, Inc. (PRTK)

Stock Price: $6.80 USD 0.06 (0.89%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $6.97 +0.17 (2.50%) Jan 15, 6:50 PM
Market Cap 295.36M
Revenue (ttm) 39.87M
Net Income (ttm) -98.90M
Shares Out 45.48M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.80
Previous Close $6.74
Change ($) 0.06
Change (%) 0.89%
Day's Open 6.70
Day's Range 6.57 - 6.88
Day's Volume 269,364
52-Week Range 2.67 - 7.14

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 5 days ago

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a dea...

Other stocks mentioned: ARGX, EYPT, GILD, GRCL, INO, LLY, ZLAB
GlobeNewsWire - 1 week ago

Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc. Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.

GuruFocus - 1 month ago

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), positio...

Other stocks mentioned: BHC, CHMA
GlobeNewsWire - 1 month ago

BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel l...

Seeking Alpha - 1 month ago

Nuzyra launch trajectory is top of class compared with other antibiotics. BARDA deal signed late 2019 is worth $285M.

GlobeNewsWire - 2 months ago

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel l...

Seeking Alpha - 2 months ago

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Paratek (PRTK) delivered earnings and revenue surprises of 24.59% and 14.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 2 months ago

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel l...

GlobeNewsWire - 2 months ago

Key Highlights Include Data on NUZYRA as an Alternative to Standard of Care to Reduce Clostridioides Difficile Infections and Real-World Experience with NUZYRA for Nontuberculous Mycobacterial...

Seeking Alpha - 3 months ago

Paratek Pharmaceuticals: Undervalued Antibiotics Play With A Fighting Chance

GlobeNewsWire - 4 months ago

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...

GlobeNewsWire - 4 months ago

BOSTON, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of nove...

Seeking Alpha - 5 months ago

Paratek Pharmaceuticals, Inc.(PRTK) CEO Evan Loh on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Paratek (PRTK) delivered earnings and revenue surprises of -278.57% and -72.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 5 months ago

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.3% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 5 months ago

BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

GlobeNewsWire - 5 months ago

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

Zacks Investment Research - 5 months ago

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 7 months ago

BOSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel ...

Seeking Alpha - 8 months ago

Paratek Plods Along

Seeking Alpha - 8 months ago

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 8 months ago

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose 2.1% in pre-market trading after the company reported Q1 results.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals

GlobeNewsWire - 10 months ago

Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020 Purchase of the first 2,500 treatment courses of NUZYRA expected in the first half of 2020

Seeking Alpha - 10 months ago

Paratek Revenue Ramp-Up Is Underappreciated By The Market And Should Drive Stock Price Gains

Seeking Alpha - 10 months ago

Paratek Pharmaceuticals: A Bright 2020 Ahead

Seeking Alpha - 10 months ago

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Paratek (PRTK) delivered earnings and revenue surprises of 21.36% and 87.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 10 months ago

BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

Seeking Alpha - 11 months ago

Paratek Pharmaceuticals: The Best Bet In A Bad Space

Zacks Investment Research - 1 year ago

Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

Other stocks mentioned: AM, CLVS, CPE, GGB
Zacks Investment Research - 1 year ago

Investors need to pay close attention to Paratek Pharmaceuticals (PRTK) stock based on the movements in the options market lately.

24/7 Wall Street - 1 year ago

When stocks rally almost 40% in a single trading session, it tends to draw some new attention.

24/7 Wall Street - 1 year ago

Some government contracts can make or break companies that supply or offer services to the government.

Market Watch - 1 year ago

Shares of Paratek Pharmaceuticals Inc. PRTK, -4.84% jumped 42% in premarket trading on Thursday on heavy volume after the company said it was awarded a five-year government contract worth up t...

GlobeNewsWire - 1 year ago

- Total award valued at up to $285 million 

Benzinga - 1 year ago

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

Other stocks mentioned: AKCA, AMAG, AXSM, CRON, EIDX, HRTX, LGND, PTE, VKTX, XON, ZIOP
GlobeNewsWire - 1 year ago

BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innov...

Investopedia - 1 year ago

While trade relations and tax-loss selling are causes for concern, opportunities for short-term and swing traders remain abundant.

Other stocks mentioned: AAU, ABEV, BW, GERN, SYNC
Seeking Alpha - 1 year ago

Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

BOSTON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innov...

Zacks Investment Research - 1 year ago

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

BOSTON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innov...

GlobeNewsWire - 1 year ago

BOSTON, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innov...

GlobeNewsWire - 1 year ago

Data highlight Paratek’s commitment to further understanding safety and efficacy of NUZYRA® (omadacycline) in unique population subsets Data highlight Paratek’s commitment to further understan...

Zacks Investment Research - 1 year ago

Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

About PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycli... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Evan Loh
Employees
101
Stock Exchange
NASDAQ
Ticker Symbol
PRTK
Full Company Profile

Financial Performance

In 2019, PRTK's revenue was $16.54 million, a decrease of -3.35% compared to the previous year's $17.12 million. Losses were -$128.79 million, 14.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for PRTK stock is "Strong Buy." The 12-month stock price forecast is 20.25, which is an increase of 197.79% from the latest price.

Price Target
$20.25
(197.79% upside)
Analyst Consensus: Strong Buy